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Background:  Inflammatory and thrombotic biomarkers can help identify patients at high risk for subsequent major adverse cardiovascular events 
(MACE). However, their utility in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention 
(PCI), especially with DES has not been evaluated.
Methods:  23 inflammatory and thrombotic biomarkers were measured at enrollment and just prior to discharge in 502 STEMI patients enrolled 
in a formal substudy of the HORIZONS-AMI trial, and analyzed in a central core laboratory. All patients underwent primary PCI with TAXUS paclitaxel-
eluting stents. We divided patients in tertiles based on biomarker levels and explored associations between biomarkers and MACE (composite of 
death, reinfarction, target vessel revascularization for ischemia, and stroke) up to 3 years follow-up. For biomarkers measured at discharge, only 
out-of hospital events were analyzed.
Results:  The 3-Year MACE rate was 17.6% (n=87). Brain natriuretic peptide (BNP), cystatin-C, d-dimer, measured at baseline, and adiponectin, 
angiotensinogen, and myeloperoxidase measured at discharge were predictive of 3-year MACE (Table 1). No association was found between hs-CRP 
and 3-year MACE. Multivariate analysis models will be available at time of presentation.
Conclusion: BNP, cystatin-c, d-dimer, measured at enrollment, and adiponectin, angiotensinogen, and myeloperoxidase upon discharge may be 
associated with 3-year MACE after STEMI. 
